An observational study evaluated more than 1000 patients with metastatic melanoma with BRAF V600 mutation and treated in the first line with either BRAFi/MEKi or ICIs (PD-1 single agent or combined PD-1/CTLA-4 antibodies), included in the EUMelaReg treatment registry [55]. The gene discussed is BRAF; the disease is metastatic melanoma.